- Home
- CIO vs IMMP Comparison
CIO vs IMMP Comparison
Compare CIO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- IMMP
- Stock Information
- Founded
- CIO 2013
- IMMP 1987
- Country
- CIO Canada
- IMMP Australia
- Employees
- CIO N/A
- IMMP N/A
- Industry
- CIO Real Estate Investment Trusts
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- CIO Real Estate
- IMMP Health Care
- Exchange
- CIO Nasdaq
- IMMP Nasdaq
- Market Cap
- CIO 278.5M
- IMMP 256.1M
- IPO Year
- CIO 2014
- IMMP N/A
- Fundamental
- Price
- CIO $6.89
- IMMP $1.72
- Analyst Decision
- CIO Hold
- IMMP Buy
- Analyst Count
- CIO 1
- IMMP 1
- Target Price
- CIO N/A
- IMMP $7.00
- AVG Volume (30 Days)
- CIO 291.2K
- IMMP 139.4K
- Earning Date
- CIO 11-06-2025
- IMMP 02-22-2026
- Dividend Yield
- CIO 4.36%
- IMMP N/A
- EPS Growth
- CIO N/A
- IMMP N/A
- EPS
- CIO N/A
- IMMP N/A
- Revenue
- CIO $163,795,000.00
- IMMP $3,306,742.00
- Revenue This Year
- CIO $0.32
- IMMP N/A
- Revenue Next Year
- CIO $3.20
- IMMP N/A
- P/E Ratio
- CIO N/A
- IMMP N/A
- Revenue Growth
- CIO N/A
- IMMP 31.28
- 52 Week Low
- CIO $4.19
- IMMP $1.32
- 52 Week High
- CIO $7.01
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- CIO 41.01
- IMMP 38.74
- Support Level
- CIO $6.87
- IMMP $1.78
- Resistance Level
- CIO $6.93
- IMMP $1.95
- Average True Range (ATR)
- CIO 0.03
- IMMP 0.09
- MACD
- CIO -0.00
- IMMP -0.01
- Stochastic Oscillator
- CIO 35.71
- IMMP 23.33
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.